# Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

> **NCT00064727** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 50 (—)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** Avandia (Rosiglitazone)
- **DRUG:** Avanclia (Rosiqlitazone)

## Key facts

- **NCT ID:** NCT00064727
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07-09
- **Primary completion:** —
- **Final completion:** 2007-04-11
- **Target enrollment:** 50 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064727, "Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00064727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*